Physician profile
Thomas Leach
NPI 1841292299
$2,886.46
in general payments reported to CMS, 2019-2025
20 companies · $495 in 2025
The $495 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $173 · 2021: $106 · 2022: $321 · 2023: $744 · 2024: $561 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,799.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $755.06 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $488.66 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $416.41 | 2021-2025 | Azstarys |
| Cranial Technologies, INC | $229.65 | 2019-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $195.84 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $134.19 | 2019-2023 | Vaxneuvance, Rotateq, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $128.61 | 2024-2025 | |
| Pfizer INC. | $86.33 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $71.06 | 2023-2024 | Qelbree, Qelbree |
| Kaleo, INC. | $65.86 | 2019-2020 | |
| Shire North American Group INC | $63.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.64 | 2020-2021 | |
| Phadia US INC. | $45.22 | 2024-2025 | Immunocap |
| Neos Therapeutics, Lp | $44.70 | 2019-2022 | |
| Alk-Abello, INC | $28.01 | 2025 | Neffy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $17.38 | 2025 | Zelsuvmi |
| Ars Pharmaceuticals Operations, INC. | $15.05 | 2025 | Neffy |
| Vertical Pharmaceuticals, LLC | $14.71 | 2025 | Relexxii |
| Arbor Pharmaceuticals, INC. | $14.06 | 2019 | |
| Genentech USA, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Leach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.